(Total Views: 677)
Posted On: 11/03/2021 7:53:15 PM
Post# of 151636
The greenwich life/GLSI therapy, GP2, does not treat TNBC.
Their treatment is in a immunotherapy administered following surgery in combination with Herceptin for HER2 patients. Phase 2 results indicate 5 year survival improving from 89% on Herceptin alone to nearly 100% with immunotherapy.
The treatment is a peptide that appears to sensitive T cells, which with concurrent administration of GM-CSF, produces a large population of cytotoxic T cells specific to the HER2 protein.
This seems very promising for this subset of breast CA patients, but not helpful for TNBC.
I do not believe, having looked at PRs for last two years, that there has been a BTD filing.
Their treatment is in a immunotherapy administered following surgery in combination with Herceptin for HER2 patients. Phase 2 results indicate 5 year survival improving from 89% on Herceptin alone to nearly 100% with immunotherapy.
The treatment is a peptide that appears to sensitive T cells, which with concurrent administration of GM-CSF, produces a large population of cytotoxic T cells specific to the HER2 protein.
This seems very promising for this subset of breast CA patients, but not helpful for TNBC.
I do not believe, having looked at PRs for last two years, that there has been a BTD filing.
(6)
(0)Scroll down for more posts ▼
